Researchers
Academic excellence, industry experience and regulatory involvement are essential to bridge the training gap that currently exists between training drug development scientists expertise in formulation science as well as a thorough understanding of regulatory science. PEARRL will provide a comprehensive, interdisciplinary and multi-sectorial training programme that will imbue ESRs with a wide range of technological and transferable skills to ensure their high employability.
|
ESR 1: Niklas Köhl
Lipid based formulations (LBF) as bio-enabling formulation technology
Institute: University College Cork, School of Pharmacy |
|
ESR 2: Felix DitzingerSupersaturating oral delivery systems of poorly water-soluble compounds produced by hot melt extrusion
Institute: University of Applied Sciences & Arts Northwestern Switzerland, Institute of Pharma Technology |
|
ESR 3: Daniel Price
Development of novel mesoporous silica-based formulations
Institute: Merck Group, Molecule Characterisation |
|
ESR 4: Georgia TsakiridouAmorphous Solid Dispersion (ASDs) formulations for per os administered bio-enabling drug products
Institute: Pharmathen SA, Product Design & Evaluation |
|
ESR 5: Sandra JankovicNovels in vitro tools and modeling to support solid dispersion formulation development
Institute: University of Applied Sciences & Arts Northwestern Switzerland, Institute of Pharma Technology |
|
ESR 6: Chara Litou
Transfer model utility – investigation of gastro-intestinal (GI) supersaturation and precipitation from discovery to regulatory submission
Institute: Johann Wolfgang Goethe University, Institute of Pharmaceutical Technology |
|
ESR 7: Christina PentafragkaDeveloping in vitro tools to forecast gastrointestinal drug transfer in the fed state
Institute: National and Kapodistrian University of Athens, Faculty of Pharmacy |
|
ESR 8: Rafael Leal Monteiro Paraiso
A new approach to setting bioequivalence limits using Physiologically based Pharmacokinetic (PBPK) modelling
Institute: Johann Wolfgang Goethe University, Institute of Pharmaceutical Technology |
|
ESR 9: Laura Henze
Exploring the utility of the porcine model for predicting bio-enabling oral drug products performance in humans
Institute: University College Cork, School of Pharmacy |
|
ESR 10: Patrick O'Dwyer
Small-scale dissolution assays for evaluating API and formulation behaviour
Institute: Pion Inc. (UK) Ltd. |
|
ESR 11: Marina Statelova
Developing new in vitro and in vivo methods to predict performance of paediatric formulations
Institute: National and Kapodistrian University of Athens, Faculty of Pharmacy |
|
ESR 12: Mariana Guimarães
Developing in vitro and in silico approaches to predict clinical outcomes with a special focus on paediatrics
Institute: University of Bath, School of Pharmacy |
|
ESR 13: Ioannis Loisios-Konstantinidis
Extension of biowaivers to BCS class II compound using biorelevant dissolution testing
Institute: Johann Wolfgang Goethe University, Institute of Pharmaceutical Technology |
|
ESR 14: Alexandra-Roxana Ilie
Developing in vitro and in silico models to predict in vivo performance of supersaturated Self-nano-emulsifying drug delivery systems
Institute: Janssen Pharmaceutical N.V., Faculty of Health and Medical Sciences |
|
ESR 15: Angela EffingerDeveloping in vitro and in silico approaches to predict the impact of gastrointestinal disease states on drug product performance
Institute: University of Bath, School of Pharmacy |
